Matinas BioPharma Holdings, Inc.
ASE: MTNBLive Quote
📈 ZcoreAI Score
Our AI model analyzes Matinas BioPharma Holdings, Inc.'s price action across multiple timeframes using regression channels and statistical scoring.
Get MTNB Z-Score →About Matinas BioPharma Holdings, Inc.
Healthcare
Biotechnology
Matinas BioPharma Holdings, Inc., a clinical-stage biopharmaceutical company, identifies and develops pharmaceutical products using its lipid nanocrystal (LNC) platform technology. The company's LNC delivery technology platform utilizes lipid nanocrystals for the delivery of small molecules, nucleic acids, gene therapies, vaccines, proteins, and peptides. Its lead product candidate is MAT2203, an oral formulation of amphotericin B that is starting Phase 3 clinical trials for the treatment of aspergillosis and cryptococcosis, as well as prevention of invasive fungal infections in patients due to immunosuppressive therapy. It offers MAT2501, an orally administered formulation of amikacin. The company has strategic collaborations with the National Institute of Allergy and Infectious Diseases; BioNTech SE to evaluate the combination of mRNA formats with the LNC platform; and Genentech Inc. to develop oral formulations. The company was incorporated in 2013 and is based in Bedminster, New Jersey.
📊 Fundamental Analysis
Matinas BioPharma Holdings, Inc. demonstrates a profit margin of 0.0%, which is below the sector average, suggesting competitive pressure.
Return on Equity (ROE) is -166.6%, which indicates that capital utilization is currently under pressure.
At a current price of $0.50, MTNB currently trades near the bottom of its 52-week range (1%), indicating potential value or weakness (Range: $0.48 - $3.09).
🏥 Financial Health
🔴
Profit Margin
Weak
✅
Debt/Equity
Excellent
🔴
Return on Equity
Weak
🔴
Beta (Risk)
High Volatility
Key Financials
Market Cap
$3.20M
Trailing P/E
--
Forward P/E
-0.17
Beta (5Y)
1.40
52W High
$3.09
52W Low
$0.48
Avg Volume
27K
Day High
Day Low